Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and mal…
| Periodo | 2023-02 | 2022-04 | 2022-04 |
|---|---|---|---|
| Real | $-0.21 | $-0.19 | $-0.19 |
| Estimado | $-0.32 | $-0.32 | $-0.30 |
| Sorpresa | +34.4% | +40.6% | +36.7% |
| Métrica | SEQUA.BR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 77.0% | 57.4% | +19.6% |
| Operating Margin | -4052.7% | -34.4% | -4018.3% |
| Net Margin | -4572.4% | -32.5% | -4540.0% |
| FCF Margin | -4180.7% | -12.6% | -4168.1% |
| ROE | — | -39.2% | — |
| ROA | -322.4% | -30.9% | -291.4% |
| Current Ratio | 0.32 | 2.73 | -2.41 |
| Debt / Equity | -0.46 | 0.28 | -0.74 |
| Tendencia (Piotroski) | FY23 | FY22 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -322.4% | — |
| ✗Flujo de caja operativo positivo | −€29M | −€27M |
| ✗Rentabilidad sobre activos al alza | -322.4% | -118.2% |
| ✓Caja operativa/activos supera al ROA | -287.7% | ROA -322.4% |
| ✗Menos deuda a largo plazo | 88.8% | 46.9% |
| ✗Mejor liquidez (ratio corriente) | 0.32 | 1.52 |
| ✗Sin aumentar el nº de acciones | 27M | 23M |
| ✗Margen bruto al alza | 77.0% | 77.8% |
| ✓Rotación de activos al alza | 0.07 | 0.04 |
| Calidad del negocio | FY23 |
|---|---|
| ✗Margen FCF > 10 % | -4180.7% |
| ✓ROCE > 10 % | 308.2% |
| ✗Ventas > 5 %/año (3 años) | -9.6% |
| ✓Deuda neta/EBITDA < 3x | -0.5x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 99.8% |
Sequana Medical cotiza a 0.61 EUR y tiene una capitalización bursátil de €48M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud